

Charles D Blanke

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5503388/publications.pdf>

Version: 2024-02-01

38
papers

3,552
citations

471061

17
h-index

360668

35
g-index

38
all docs

38
docs citations

38
times ranked

4219
citing authors

#	ARTICLE	IF	CITATIONS
1	Survival in Young-Onset Metastatic Colorectal Cancer: Findings From Cancer and Leukemia Group B (Alliance)/SWOG 80405. <i>Journal of the National Cancer Institute</i> , 2022, 114, 427-435.	3.0	24
2	IGF-Binding Proteins, Adiponectin, and Survival in Metastatic Colorectal Cancer: Results From CALGB (Alliance)/SWOG 80405. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkaa074.	1.4	6
3	Sex and Adverse Events of Adjuvant Chemotherapy in Colon Cancer: An Analysis of 34,640 Patients in the ACCENT Database. <i>Journal of the National Cancer Institute</i> , 2021, 113, 400-407.	3.0	44
4	Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART). , 2021, 9, e002990.		58
5	Clinicopathological and Molecular Characteristics of Early-Onset Stage III Colon Adenocarcinoma: An Analysis of the ACCENT Database. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1693-1704.	3.0	25
6	Racial differences in survival and response to therapy in patients with metastatic colorectal cancer: A secondary analysis of CALGB/SWOG 80405 (Alliance A151931). <i>Cancer</i> , 2021, 127, 3801-3808.	2.0	6
7	Diabetes and Clinical Outcome in Patients With Metastatic Colorectal Cancer: CALGB 80405 (Alliance). <i>JNCI Cancer Spectrum</i> , 2020, 4, pkz078.	1.4	22
8	Body Mass Index and Weight Loss in Metastatic Colorectal Cancer in CALGB (Alliance)/SWOG 80405. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkaa024.	1.4	8
9	Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP) Tj ETQq1 1 0.784314 rgBT /Overlo 5.1 68		
10	In response: Diabetes is a risk factor for the progression and prognosis of COVID-19. <i>Diabetes/Metabolism Research and Reviews</i> , 2020, 36, e3331.	1.7	12
11	Enrollment of adolescents and young adults onto SWOG cancer research network clinical trials: A comparative analysis by treatment site and era. <i>Cancer Medicine</i> , 2020, 9, 2146-2152.	1.3	18
12	Letters to the Editor. <i>Journal of Law, Medicine and Ethics</i> , 2020, 48, 800-801.	0.4	1
13	Associations of Physical Activity With Survival and Progression in Metastatic Colorectal Cancer: Results From Cancer and Leukemia Group B (Alliance)/SWOG 80405. <i>Journal of Clinical Oncology</i> , 2019, 37, 2620-2631.	0.8	51
14	The Gift of Dying With Control. <i>Practical Radiation Oncology</i> , 2019, 9, 387-388.	1.1	1
15	Current Activities of the Coalition of Cancer Cooperative Groups. <i>Journal of the National Cancer Institute</i> , 2019, 111, 11-18.	3.0	4
16	Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 2392.	3.8	670
17	Responding to Patient Requests for Hastened Death: Physician Aid in Dying and the Clinical Oncologist. <i>Journal of Oncology Practice</i> , 2017, 13, 693-699.	2.5	7
18	Duration of Adjuvant Therapy for Patients With Gastrointestinal Stromal Tumors. <i>JAMA Oncology</i> , 2016, 2, 721.	3.4	5

#	ARTICLE	IF	CITATIONS
19	American Society of Clinical Oncology Statement: Human Papillomavirus Vaccination for Cancer Prevention. <i>Journal of Clinical Oncology</i> , 2016, 34, 1803-1812.	0.8	83
20	S0502: A SWOG Phase III Randomized Study of Imatinib, With or Without Bevacizumab, in Patients With Untreated Metastatic or Unresectable Gastrointestinal Stromal Tumors. <i>Oncologist</i> , 2015, 20, 1353-1354.	1.9	10
21	Age-Related Cataract in Men in the Selenium and Vitamin E Cancer Prevention Trial Eye Endpoints Study. <i>JAMA Ophthalmology</i> , 2015, 133, 17.	1.4	38
22	The Globalization of Cooperative Groups. <i>Seminars in Oncology</i> , 2015, 42, 693-712.	0.8	6
23	Pathologic and Molecular Features Correlate With Long-Term Outcome After Adjuvant Therapy of Resected Primary GI Stromal Tumor: The ACOSOG Z9001 Trial. <i>Journal of Clinical Oncology</i> , 2014, 32, 1563-1570.	0.8	252
24	Comparison of Dietary and Lifestyle Habits Among Stage III and Metastatic Colorectal Cancer Patients: Findings from CALGB 89803 and CALGB 80405. <i>Clinical Colorectal Cancer</i> , 2013, 12, 95-102.	1.0	17
25	The Predictive and Prognostic Value of Sex in Early-Stage Colon Cancer: A Pooled Analysis of 33,345 Patients from the ACCENT Database. <i>Clinical Colorectal Cancer</i> , 2013, 12, 179-187.	1.0	27
26	Long-Term Results From a Randomized Phase II Trial of Standard- Versus Higher-Dose Imatinib Mesylate for Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing <i>KIT</i> . <i>Journal of Clinical Oncology</i> , 2008, 26, 620-625.	0.8	922
27	Phase III Randomized, Intergroup Trial Assessing Imatinib Mesylate At Two Dose Levels in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing the Kit Receptor Tyrosine Kinase: S0033. <i>Journal of Clinical Oncology</i> , 2008, 26, 626-632.	0.8	951
28	Gastrointestinal stromal tumours: three perspectives on current diagnosis and therapy. <i>European Journal of Cancer</i> , Supplement, 2006, 4, 1-3.	2.2	1
29	Gastrointestinal stromal tumors: Imatinib and beyond. <i>Current Treatment Options in Oncology</i> , 2006, 7, 427-437.	1.3	28
30	A phase I study of 5-fluorouracil, leucovorin, and celecoxib in patients with incurable colorectal cancer. <i>Prostaglandins and Other Lipid Mediators</i> , 2005, 75, 169-172.	1.0	14
31	GIST: Not Just for Surgeons Anymore!. <i>World Journal of Surgery</i> , 2005, 29, 362-362.	0.8	2
32	Low dose versus high dose imatinib for gastrointestinal stromal tumors. <i>Nature Reviews Gastroenterology & Hepatology</i> , 2005, 2, 76-77.	1.7	0
33	State-of-the Art Therapy for Gastrointestinal Stromal Tumors. <i>Cancer Investigation</i> , 2005, 23, 274-280.	0.6	66
34	Role of COX-2 Inhibitors in Cancer Therapy. <i>Cancer Investigation</i> , 2004, 22, 271-282.	0.6	22
35	Chemotherapy with Cyclooxygenase-2 Inhibitors in the Treatment of Malignant Disease: Pre-Clinical Rationale and Preliminary Results of Clinical Trials. , 2003, 37, 243-260.		2
36	Celecoxib with chemotherapy in colorectal cancer. <i>Oncology</i> , 2002, 16, 17-21.	0.4	8

#	ARTICLE	IF	CITATIONS
37	Gastrointestinal stromal tumors. Current Treatment Options in Oncology, 2001, 2, 485-491.	1.3	64
38	A phase I study of vitamin E, 5-fluorouracil and leucovorin for advanced malignancies. Investigational New Drugs, 2001, 19, 21-27.	1.2	9